Sun Pharmaceutical (SUNPHARMA) — concall transcript

📢 Key Event
Sun Pharma reported Q3 FY24 results with 9.5% YoY sales growth and 19.7% YoY net profit growth excluding exceptional items, driven by specialty performance.

🔄 What Changed
Specialty sales mix improved, reducing material costs to 22.5% of sales; R&D spend increased; interim dividend of ₹8.50/share announced.

🔮 What's Next
No near-term dividend/share buyback plans; focus on high-return investments; GL0034 Phase II to start in second half of next year; pricing strategy in Europe tied to value metrics.

💡 Investor Takeaway
Sun Pharma is prioritizing high-return investments over shareholder distributions despite strong cash reserves, signaling strategic reinvestment over immediate returns.

Sun Pharmaceutical reported consolidated sales of ₹121,569 crores (9.5% YoY growth) and EBITDA of ₹34,768 crores (28.1% margin) for Q3 FY24, with net profit of ₹25,238 crores (19.7% YoY growth excluding exceptional items). Specialty sales drove growth, particularly in India (11.4% YoY) and U.S. ($477M), while emerging markets contributed $252M. Management highlighted improved specialty mix reducing material costs to 22.5% of sales and increased R&D investment. An interim dividend of [amount context mismatch] per share was announced, with cash reserves exceeding $2 billion. Forward guidance remains focused on high-return investments rather than buybacks.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹4,63,791.45 Cr P/E: 38.4 ROE: 14.6% ROCE: 18.7% Div Yield: 0.83%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How will GL0034 impact future growth timelines?" "What is the expected timeline for Taro merger regulatory approvals?" "Why no buybacks despite $2B+ cash reserves?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 31 December 2023

ULTRACEMCO UltraTech Cement Ltd concall transcript BEL Bharat Electronics Ltd concall transcript INDIGO Interglobe Aviation Ltd concall transcript M&M Mahindra & Mahindra Ltd concall transcript SBIN State Bank of India concall transcript TITAN Titan Company Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd